[Remarkable pain relief in the treatment with high-dose medroxyprogesterone acetate in advanced prostatic carcinoma].
A 60-year-old man was admitted to our hospital because of lumbago due to a metastatic bone tumor that originated from the prostate. Previously, he had been treated with 500 mg/kg of diethylstilbestrol diphosphate and 75 mg/day of chlormadinone acetate. At our hospital, he was given 470.1 mg/day of estramustine sodium phosphate and a bilateral orchiectomy was performed. However, he felt increased lumbago. Thus, a dose of 1200 mg/day of medroxyprogesterone acetate was started. Although the histology of his prostate and bone scintigram did not change, the patient no longer felt lumbago from about 2 weeks after the start of this treatment. Six months later, he remains free of lumbago. In this report, we describe the effect of high-dose medroxyprogesterone acetate on the clinical course, and the plasma and urine levels of the hormones.
Sasagawa
I
I
Dept. of Urology, Saiseikai Fukushima General Haspital.
Satomi
S
S
Katayama
T
T
D000324:Adrenocorticotropic Hormone / Q000097:blood; D001416:Back Pain / Q000188:drug therapy; D001859:Bone Neoplasms / Q000188:drug therapy / Q000503:physiopathology / Q000556:secondary; D001842:Bone and Bones / Q000000981:diagnostic imaging; D002715:Chlormadinone Acetate / Q000627:therapeutic use; D003687:Dehydroepiandrosterone / Q000097:blood; D006801:Humans; D008297:Male; D008525:Medroxyprogesterone / Q000008:administration & dosage / Q000031:analogs & derivatives* / Q000627:therapeutic use; D017258:Medroxyprogesterone Acetate; D008875:Middle Aged; D010148:Intractable Pain / Q000188:drug therapy*; D010166:Palliative Care; D011471:Prostatic Neoplasms / Q000188:drug therapy / Q000503:physiopathology*; D011877:Radionuclide Imaging
D002715:Chlormadinone Acetate; D003687:Dehydroepiandrosterone; D000324:Adrenocorticotropic Hormone; D017258:Medroxyprogesterone Acetate; D008525:Medroxyprogesterone